<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8288D666-63BA-4F6B-8B3B-EDEB230048CB"><gtr:id>8288D666-63BA-4F6B-8B3B-EDEB230048CB</gtr:id><gtr:name>Genewerks</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/75AEC807-087D-48FC-A11C-9FD0D3DCB516"><gtr:id>75AEC807-087D-48FC-A11C-9FD0D3DCB516</gtr:id><gtr:name>Albert Ludwigs University of Freiburg</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6F5F667B-3844-49DF-948F-FCA983560AF9"><gtr:id>6F5F667B-3844-49DF-948F-FCA983560AF9</gtr:id><gtr:name>Hannover Medical School</gtr:name><gtr:address><gtr:line1>Carl-Neuberg-Str. 1</gtr:line1><gtr:postCode>D-30625</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E34F39A1-E98F-45E3-A8AF-57F7D0B7A942"><gtr:id>E34F39A1-E98F-45E3-A8AF-57F7D0B7A942</gtr:id><gtr:name>Necker-Enfants Malades Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/80DA3CCF-F0C1-43B8-9FBC-BD0DE9772B15"><gtr:id>80DA3CCF-F0C1-43B8-9FBC-BD0DE9772B15</gtr:id><gtr:name>Ospedale San Raefaelle</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/31C8C3D6-0F45-4639-8C94-78C0C503AB52"><gtr:id>31C8C3D6-0F45-4639-8C94-78C0C503AB52</gtr:id><gtr:name>Genethon</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/BC0E951E-239C-4369-8E5A-6E82F9B06B50"><gtr:id>BC0E951E-239C-4369-8E5A-6E82F9B06B50</gtr:id><gtr:name>University of Leiden</gtr:name><gtr:address><gtr:line1>P.O. Box 9506</gtr:line1><gtr:line4>Leiden</gtr:line4><gtr:line5>2300</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Unlisted</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8288D666-63BA-4F6B-8B3B-EDEB230048CB"><gtr:id>8288D666-63BA-4F6B-8B3B-EDEB230048CB</gtr:id><gtr:name>Genewerks</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/75AEC807-087D-48FC-A11C-9FD0D3DCB516"><gtr:id>75AEC807-087D-48FC-A11C-9FD0D3DCB516</gtr:id><gtr:name>Albert Ludwigs University of Freiburg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6F5F667B-3844-49DF-948F-FCA983560AF9"><gtr:id>6F5F667B-3844-49DF-948F-FCA983560AF9</gtr:id><gtr:name>Hannover Medical School</gtr:name><gtr:address><gtr:line1>Carl-Neuberg-Str. 1</gtr:line1><gtr:postCode>D-30625</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Germany</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E34F39A1-E98F-45E3-A8AF-57F7D0B7A942"><gtr:id>E34F39A1-E98F-45E3-A8AF-57F7D0B7A942</gtr:id><gtr:name>Necker-Enfants Malades Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/80DA3CCF-F0C1-43B8-9FBC-BD0DE9772B15"><gtr:id>80DA3CCF-F0C1-43B8-9FBC-BD0DE9772B15</gtr:id><gtr:name>Ospedale San Raefaelle</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/31C8C3D6-0F45-4639-8C94-78C0C503AB52"><gtr:id>31C8C3D6-0F45-4639-8C94-78C0C503AB52</gtr:id><gtr:name>Genethon</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/BC0E951E-239C-4369-8E5A-6E82F9B06B50"><gtr:id>BC0E951E-239C-4369-8E5A-6E82F9B06B50</gtr:id><gtr:name>University of Leiden</gtr:name><gtr:address><gtr:line1>P.O. Box 9506</gtr:line1><gtr:line4>Leiden</gtr:line4><gtr:line5>2300</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Netherlands</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1BE255AB-00BF-4AA3-9E28-22D1A5562980"><gtr:id>1BE255AB-00BF-4AA3-9E28-22D1A5562980</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:surname>Antoniou</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/32C75711-61FE-40B1-B099-73E64CC6EF27"><gtr:id>32C75711-61FE-40B1-B099-73E64CC6EF27</gtr:id><gtr:firstName>Hubert</gtr:firstName><gtr:otherNames>Baburaj</gtr:otherNames><gtr:surname>Gaspar</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B0FFB06E-0C80-4114-9D30-7040F66F445B"><gtr:id>B0FFB06E-0C80-4114-9D30-7040F66F445B</gtr:id><gtr:firstName>Adrian</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Thrasher</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0600773"><gtr:id>E78B78F7-1E28-45DF-A472-251480594C38</gtr:id><gtr:title>Development of an enhanced lentiviral vector for gene therapy of ADA-SCID</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0600773</gtr:grantReference><gtr:abstractText>Adenosine deaminase deficiency is a condition in which affected children lack a functional immune system and die from infection in the first year of life. The nature of the gene defect is such that severe defects are also found in other systems of the body. Due to the limitations of other treatment options, gene therapy has recently been used with some success in correcting the immune defects. In this study we hope to build on this and test better gene therapy delivery vectors that may correct both the immune system and non-immune system problems. We will also use vectors that have improved safety profiles compared to presently used constructs. We will test our new vectors in cellular systems and also aim to correct a murine model of the disease.</gtr:abstractText><gtr:technicalSummary>Somatic gene therapy has long been held as a major goal for correction of monogenic diseases. The promise of over two decades of basic and pre-clinical research has now been realised with the demonstration of significant therapeutic effect in clinical studies on a number of severe congenital immunodeficiencies including SCID-X1 (X-linked severe combined immunodeficiency), ADA-SCID (adenosine deaminase deficient SCID) and X-CGD (X-linked chronic granulomatous disease). To date, successful gene transfer has been mediated by conventional gammaretroviral vectors which show efficient and stable integration into haematopoietic stem cells (HSC) but have also demonstrated the potential for significant side effects through inadvertent gene activation. For ADA-SCID, where the ADA gene is expressed in all somatic tissues and where clinically defects exist outside of the immune system, systemic gene delivery may have added therapeutic benefit. In this application, we aim to build on our highly promising phase I/II gene therapy trials for ADA-SCID and to develop and test vectors with improved safety profiles and enhanced ADA gene delivery. We plan to develop lentiviral vectors in which the ADA gene is transcribed from a non-viral promoter which is also under the influence of the beta-globin locus control region (LCR). Using this construct, we hope to achieve high level expression in lymphocytes to allow T and B cell development, but also beta-globin LCR driven expression in erythrocytes which may allow for greater systemic ADA expression and provide better metabolite detoxification. The use of a lentiviral construct with deleted long terminal repeat sequences and an internal promoter will also provide an improved safety profile.</gtr:technicalSummary><gtr:fund><gtr:end>2010-07-04</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-07-05</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>315127</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leiden University</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>EU consortium for collaborations with clinical partners for trials for gene therapy for SCID</gtr:description><gtr:id>A3A01DCB-3159-4861-92D3-751B2FD35D10</gtr:id><gtr:impact>Award of a H2020 EU grant</gtr:impact><gtr:outcomeId>56df01fc184cf2.88294190-3</gtr:outcomeId><gtr:partnerContribution>contributing to taking forward gene therapy for SCID in the context of a European partnership</gtr:partnerContribution><gtr:piContribution>Leading clinical trials for ADA SCID and X-linked SCID</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ospedale San Raefaelle</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:description>EU consortium for collaborations with clinical partners for trials for gene therapy for SCID</gtr:description><gtr:id>63045A81-8531-4525-962D-E314665C8E1C</gtr:id><gtr:impact>Award of a H2020 EU grant</gtr:impact><gtr:outcomeId>56df01fc184cf2.88294190-2</gtr:outcomeId><gtr:partnerContribution>contributing to taking forward gene therapy for SCID in the context of a European partnership</gtr:partnerContribution><gtr:piContribution>Leading clinical trials for ADA SCID and X-linked SCID</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Necker-Enfants Malades Hospital</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>EU consortium for collaborations with clinical partners for trials for gene therapy for SCID</gtr:description><gtr:id>B1023ACD-5750-4FD7-A87F-99692DD95FA3</gtr:id><gtr:impact>Award of a H2020 EU grant</gtr:impact><gtr:outcomeId>56df01fc184cf2.88294190-1</gtr:outcomeId><gtr:partnerContribution>contributing to taking forward gene therapy for SCID in the context of a European partnership</gtr:partnerContribution><gtr:piContribution>Leading clinical trials for ADA SCID and X-linked SCID</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Genethon</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>EU consortium for collaborations with clinical partners for trials for gene therapy for SCID</gtr:description><gtr:id>4B504A9D-1057-48AC-B191-0473DF0042A2</gtr:id><gtr:impact>Award of a H2020 EU grant</gtr:impact><gtr:outcomeId>56df01fc184cf2.88294190-4</gtr:outcomeId><gtr:partnerContribution>contributing to taking forward gene therapy for SCID in the context of a European partnership</gtr:partnerContribution><gtr:piContribution>Leading clinical trials for ADA SCID and X-linked SCID</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Albert Ludwigs University of Freiburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Center for Chronic Immunodeficiency (CCI)</gtr:department><gtr:description>EU consortium for collaborations with clinical partners for trials for gene therapy for SCID</gtr:description><gtr:id>0AB07082-1272-4A2C-8AE6-92B562DABCFC</gtr:id><gtr:impact>Award of a H2020 EU grant</gtr:impact><gtr:outcomeId>56df01fc184cf2.88294190-5</gtr:outcomeId><gtr:partnerContribution>contributing to taking forward gene therapy for SCID in the context of a European partnership</gtr:partnerContribution><gtr:piContribution>Leading clinical trials for ADA SCID and X-linked SCID</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Genewerks</gtr:collaboratingOrganisation><gtr:country>Australia, Commonwealth of</gtr:country><gtr:description>EU consortium for collaborations with clinical partners for trials for gene therapy for SCID</gtr:description><gtr:id>2FF48059-06C5-4CFD-BD8F-B6B1646D8D52</gtr:id><gtr:impact>Award of a H2020 EU grant</gtr:impact><gtr:outcomeId>56df01fc184cf2.88294190-7</gtr:outcomeId><gtr:partnerContribution>contributing to taking forward gene therapy for SCID in the context of a European partnership</gtr:partnerContribution><gtr:piContribution>Leading clinical trials for ADA SCID and X-linked SCID</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Hannover Medical School</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:department>Institute of Experimental Hematology</gtr:department><gtr:description>EU consortium for collaborations with clinical partners for trials for gene therapy for SCID</gtr:description><gtr:id>4C261036-9CA0-4874-A13C-2FC604D57460</gtr:id><gtr:impact>Award of a H2020 EU grant</gtr:impact><gtr:outcomeId>56df01fc184cf2.88294190-6</gtr:outcomeId><gtr:partnerContribution>contributing to taking forward gene therapy for SCID in the context of a European partnership</gtr:partnerContribution><gtr:piContribution>Leading clinical trials for ADA SCID and X-linked SCID</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>UCLH/UCL Biomedical Research Centre</gtr:department><gtr:description>Great Ormond Street Hospital Biomedical Research Centre Call for Project grants</gtr:description><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>BE7B2A95-15FD-423C-B644-EF7F2BF73355</gtr:id><gtr:outcomeId>fhedQRwhFvf0</gtr:outcomeId><gtr:sector>Public</gtr:sector></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>90099</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC Confidence in Concept Scheme</gtr:department><gtr:description>UCL/MRC Confidence in Concept scheme</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>00F3C0A9-EADF-484E-B44C-787472C2F053</gtr:id><gtr:outcomeId>5464b157e6b6e4.73394307</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>247565</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Development of a gene therapy vector for the treatment of Mucopolysaccharidosis type I-Hurler</gtr:description><gtr:end>2016-09-02</gtr:end><gtr:fundingOrg>Great Ormond Street Hospital Children's Charity (GOSHCC)</gtr:fundingOrg><gtr:fundingRef>W1084</gtr:fundingRef><gtr:id>D48F5478-E4B0-494A-A95C-08762BD24EF2</gtr:id><gtr:outcomeId>BoR7tc6qKLS</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>613850</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Development of a lentiviral vector for gene therapy of ADA deficiency</gtr:description><gtr:end>2012-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>3C630919-92D6-44EF-9543-FE27346648BB</gtr:id><gtr:outcomeId>okihrV17SM8</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>WE HAVE DESIGNED AND TESTED A NOVEL LENTIVIRAL VECTOR CONSTRUCT THAT IS CAPABLE OF UPREGULATED ADA EXPRESSION IN ERYTHROCYTE LINEAGES</gtr:description><gtr:id>9ADA89DD-C7D5-46A8-805D-EDBEDBB493DB</gtr:id><gtr:impact>NONE AS YET BUT FURTHER TESTING IS ONGOING AND WE EXPECT A PUBLICATION IN 2010</gtr:impact><gtr:outcomeId>B83743499B5</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>ENHANCED LENTIVIRAL VECTOR</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Orchard Therapeutics</gtr:companyName><gtr:description>Ex vivo bone marrow gene therapy company</gtr:description><gtr:id>67877C20-02F1-4A1F-8942-B9D43C82C457</gtr:id><gtr:impact>none so far but intention to take gene therapy developments to licensed medicines</gtr:impact><gtr:outcomeId>56df05b29c8cf5.18525541</gtr:outcomeId><gtr:url>http://orchard-tx.com/</gtr:url><gtr:yearCompanyFormed>2016</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>09F73F36-D3D4-4463-BF12-D5C4A272F9B5</gtr:id><gtr:title>Development of gene therapy: potential in severe combined immunodeficiency due to adenosine deaminase deficiency</gtr:title><gtr:parentPublicationTitle>Stem Cells and Cloning: Advances and Applications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ff5966f150005e4750fcd328fcef5661"><gtr:id>ff5966f150005e4750fcd328fcef5661</gtr:id><gtr:otherNames>Thrasher A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:outcomeId>CBATRuJhiLH</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E30A581-39D7-419C-BE16-547D985A0FA5</gtr:id><gtr:title>Gene therapy for ADA-SCID: defining the factors for successful outcome.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dd17b216b843d6a2bf8cc2768bf4e375"><gtr:id>dd17b216b843d6a2bf8cc2768bf4e375</gtr:id><gtr:otherNames>Gaspar HB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>pm_13307_27_23118212</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6195257-46EB-4F52-9DBD-41D8ED35C032</gtr:id><gtr:title>The ?-globin locus control region in combination with the EF1a short promoter allows enhanced lentiviral vector-mediated erythroid gene expression with conserved multilineage activity.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6db97f40240b631583b97b0f14f1b744"><gtr:id>6db97f40240b631583b97b0f14f1b744</gtr:id><gtr:otherNames>Montiel-Equihua CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>pm_13307_27_22434141</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C2DC8654-7C2D-4E9E-8D9B-8BD6947C1A91</gtr:id><gtr:title>Current progress on gene therapy for primary immunodeficiencies.</gtr:title><gtr:parentPublicationTitle>Gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/917fedf7d4ac4a5d4fbb9db6070723d7"><gtr:id>917fedf7d4ac4a5d4fbb9db6070723d7</gtr:id><gtr:otherNames>Zhang L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0969-7128</gtr:issn><gtr:outcomeId>pm_13307_27_23719067</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6F866B0F-6D46-4C8A-82E0-C6517BAB805A</gtr:id><gtr:title>Gene therapy for primary immunodeficiencies.</gtr:title><gtr:parentPublicationTitle>Human gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/389bb18dd04f9608cc69e03741418009"><gtr:id>389bb18dd04f9608cc69e03741418009</gtr:id><gtr:otherNames>Rivat C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1043-0342</gtr:issn><gtr:outcomeId>pm_13307_27_22691036</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8D811274-8F05-4F57-833E-12598AD45176</gtr:id><gtr:title>Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8e954465e7e4ad898168b5337d888000"><gtr:id>8e954465e7e4ad898168b5337d888000</gtr:id><gtr:otherNames>Carbonaro DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>5464aa6019a922.73024145</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75D2A7CC-654A-452A-81BC-F802EFC9826E</gtr:id><gtr:title>Gene therapy for monogenic disorders of the bone marrow.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3767a7e1a2a4b0d09e43ceb48f9f07ab"><gtr:id>3767a7e1a2a4b0d09e43ceb48f9f07ab</gtr:id><gtr:otherNames>Ghosh S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>56dca13d6d56f9.25849398</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02DE4D3A-52E7-4EBB-B2D5-CFB436C483A0</gtr:id><gtr:title>Gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency.</gtr:title><gtr:parentPublicationTitle>Current gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6db97f40240b631583b97b0f14f1b744"><gtr:id>6db97f40240b631583b97b0f14f1b744</gtr:id><gtr:otherNames>Montiel-Equihua CA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1566-5232</gtr:issn><gtr:outcomeId>pm_13307_27_22348551</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0600773</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>986F1CAE-CC43-4D59-8F85-A91971E4C4BE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Other</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>